Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 12/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584056 | 0.93 | ADA (0.50) | ADAIKBKBNPC1RAB9ACEPT1 | |
| SCHEMBL4584977 | 0.92 | ADA (0.59) | ADAHTR3ACEPT1 | |
| SCHEMBL4585499 | 0.89 | ADA (0.55) | ADAHTR3AMAPTSMN1; SMN2IKBKB | |
| SCHEMBL4584358 | 0.88 | ADA (0.49) | ADAHTR3AMAPTIKBKBPARP1 | |
| Hydrochloric Acid SCHEMBL4582809 | 0.88 | ADA (0.54) | ADAHTR3AMAPTSMN1; SMN2IKBKB | |
| SCHEMBL4585295 | 0.86 | ADA (0.44) | ADAMAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4584389 | 0.83 | ADA (0.41) | ADA | |
| SCHEMBL4584396 | 0.83 | ADA (0.40) | ADAIKBKB | |
| SCHEMBL4584805 | 0.82 | ADA (0.49) | ADAHTR3AMAPTKDM4EALDH1A1 | |
| SCHEMBL4584642 | 0.82 | ADA (0.65) | ADAHTR3AMAPTSMN1; SMN2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317107-B2 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | disclosed |
| US-20050159462-A1 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ASTELLAS PHARMA INC. (JP) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159462-A1 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ADA, AMPD2, AMPD1 | ADA 1/4885HTR3A 747/4885MAPT 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.